Cardiometabolic Risks in Schizophrenia and Directions for Intervention, 3: Psychopharmacological Interventions

Chittaranjan Andrade, MD

ABSTRACT

Patients with schizophrenia have increased prevalence rates for many cardiometabolic risk factors; the prevalence and severity of these risks increase after the institution of antipsychotic medication. Nearly 2 dozen different pharmacologic interventions have been trialed to prevent or attenuate antipsychotic-related cardiometabolic changes. Metformin (usually 1,000–1,500 mg/d) has emerged as the best-studied intervention; in short- and intermediate-duration randomized controlled trials, it has been shown to bring about improvements in weight and other anthropometric indices, in fasting sugar and other glycemic control indices, and in total cholesterol and other lipid metabolism indices. Topiramate and aripiprazole are other possible interventions with support in literature; besides improving metabolic outcomes, these drugs may improve indices of psychopathology, as well. Encouraging though the findings are, there are many unanswered questions that require attention in future research.


Introduction

Schizophrenia is associated with an increased prevalence of many cardiometabolic risk factors. These risk factors are evident early during the course of the illness and increase in prevalence after antipsychotic exposure. Behavioral interventions, such as dietary guidance, exercise training, and combined diet and exercise (with psychoeducation and other behavioral elements included in the package) have not been shown to consistently improve cardiovascular health indices in patients with schizophrenia and other major mental illnesses; furthermore, there are challenges to the implementation of behavioral interventions in such patients. The present article, the third in a series, examines whether pharmacologic interventions can mitigate the cardiometabolic risks.

Pharmacologic Interventions for Antipsychotic-Related Metabolic Changes

In one of the most recent and most extensive PRISMA-compliant meta-analyses on the subject, Mizuno et al4 searched several electronic databases and other sources and identified 41 published and 9 unpublished, randomized, placebo-controlled trials of pharmacologic interventions for antipsychotic-induced weight gain and other metabolic adverse effects in samples of patients (pooled N = 2,676) with schizophrenia as the commonest diagnosis.

These randomized controlled trials (RCTs) ranged from 4 to 24 (mean, 12) weeks in duration. The sample size in the individual studies was 2–207 (mean, 54). Most of the studies were conducted in North America (19 RCTs) and Asia (18 RCTs). Only 18 studies were clearly linked to industry funding. The pharmacologic interventions studied were amantadine, aripiprazole, atomoxetine, d-fenfluramine, dextroamphetamine, famotidine, fluoxetine, intranasal insulin, metformin, metformin with sibutramine, modafinil, nizatidine, orlistat, phenylpropanolamine, reboxetine, reboxetine with betahistine, rimoban, rimonabant, rosiglitazone, sibutramine, telmisartan, topiramate, and zonisamide. Most of these agents were investigated in 1–3 RCTs; nizatidine and sibutramine were each investigated in 4 RCTs, and metformin was studied in monotherapy in 10 RCTs. One RCT investigated a drug that had a code number but no name.

In 13 RCTs, pharmacologic interventions were instituted along with antipsychotic medication with a view to prevent metabolic changes; in the remaining RCTs, the pharmacologic interventions were trialed for the attenuation of existing antipsychotic-induced metabolic changes. The primary antipsychotic was clozapine or olanzapine in 49 RCTs. The primary antipsychotic was clozapine or olanzapine in 49 RCTs.

Data on weight change were available in 40 RCTs; 21 RCTs provided data on glucose metabolism, and 16, on lipid parameters. Data for meta-analysis were available from only the published studies. Only 6 RCTs showed a low risk of bias; in the rest, risk of bias was frequently unclear because of poor reporting on the relevant variables.
The metabolic syndrome and its components are common in schizophrenia. Antipsychotic treatment plays a significant role in the genesis and worsening of these metabolic risks.

Out of nearly 2 dozen pharmacologic interventions trialed, metformin (1,000-1,500 mg/d) has emerged as the best treatment option for improvement in anthropometric indices and indices of glucose and lipid metabolism. Blood pressure, however, does not change with metformin treatment.

Topiramate and aripiprazole are other possible interventions; these may also improve psychopathology outcomes.

### Clinical Points

- The metabolic syndrome and its components are common in schizophrenia. Antipsychotic treatment plays a significant role in the genesis and worsening of these metabolic risks.
- Out of nearly 2 dozen pharmacologic interventions trialed, metformin (1,000-1,500 mg/d) has emerged as the best treatment option for improvement in anthropometric indices and indices of glucose and lipid metabolism. Blood pressure, however, does not change with metformin treatment.
- Topiramate and aripiprazole are other possible interventions; these may also improve psychopathology outcomes.

### Table 1. Pharmacologic Interventions for Antipsychotic-Related Metabolic Adverse Effects in Schizophrenia: Weight Outcomes

<table>
<thead>
<tr>
<th>Outcome</th>
<th>Metformin (9 RCTs)</th>
<th>Other Treatments</th>
</tr>
</thead>
<tbody>
<tr>
<td>Weight Loss</td>
<td>Slightly but significantly lower fasting blood sugar levels by a mean of 3.18 mg/dL</td>
<td>Not available</td>
</tr>
<tr>
<td>Hypertension</td>
<td>No change</td>
<td>No change</td>
</tr>
<tr>
<td>Lipids</td>
<td>No change</td>
<td>No change</td>
</tr>
<tr>
<td>Glucose</td>
<td>No change</td>
<td>No change</td>
</tr>
</tbody>
</table>

### Table 2. Pharmacologic Interventions for Antipsychotic-Related Metabolic Adverse Effects in Schizophrenia: Glucose and Lipid Outcomes

<table>
<thead>
<tr>
<th>Outcome</th>
<th>Metformin (9 RCTs)</th>
<th>Other Treatments</th>
</tr>
</thead>
<tbody>
<tr>
<td>Glucose</td>
<td>Slightly but significantly lower fasting blood sugar levels by a mean of 3.18 mg/dL</td>
<td>Not available</td>
</tr>
<tr>
<td>Lipids</td>
<td>No change</td>
<td>No change</td>
</tr>
</tbody>
</table>

Important findings from this meta-analysis are presented in Tables 1 and 2. In summary, there was a reasonably strong evidence base to support the use of only 1 drug, metformin, for either prevention or attenuation of antipsychotic-induced metabolic changes. Metformin significantly prevented weight gain or reduced weight; it was associated with decrease in fasting blood sugar, glycosylated hemoglobin, fasting insulin levels, and insulin resistance. Metformin was also associated with a reduction in triglyceride levels. Not all of these changes were clinically significant, and there was evidence of heterogeneity as well as publication bias. Whereas topiramate was associated with substantial metabolic benefit, the evidence base comprised only 1 RCT. An interesting finding from a subgroup analysis was that the benefits in first-episode patients were larger in magnitude, thus encouraging the earlier use of pharmacologic interventions to prevent or treat antipsychotic-related metabolic complications.

### Metformin for Antipsychotic-Related Metabolic Changes

Zheng et al described a PRISMA-compliant systematic review and meta-analysis of only metformin vs placebo RCTs; the advantage of this over the earlier meta-analysis is that, besides conducting an updated search of the English language database, the authors included Chinese language RCTs.

There were 21 RCTs (pooled N = 1,547) in all, 11 RCTs published in English and 10 in Chinese. Of these, 15 RCTs had been conducted in China. In 5 studies, metformin had been administered at the time of antipsychotic initiation to prevent antipsychotic-related metabolic changes; in the remaining 16 studies, the use of metformin was to attenuate antipsychotic-related metabolic changes. The sample size in these RCTs was 39–148 (median, 70). Of the 1,547 patients, 778 received metformin and 769 received placebo. Metformin was dosed at 250–1,750 mg/d. Olanzapine and clozapine were the most common antipsychotics in these studies. The studies were 6–24 (median, 12) weeks in duration. In general, there seemed to be no evidence of publication bias.

Important findings from the meta-analysis are presented in Table 3. In summary, metformin significantly reduced body weight, body mass index, and waist circumference,
Metformin was associated with less weight gain or greater weight loss than placebo (SMD, 0.61; 95% CI, 0.44−0.77; 19 RCTs; N = 1,277). Metformin was correspondingly associated with a significantly greater reduction in BMI (SMD, 0.69). Heterogeneity was 51%−73%.

2. Metformin was associated with significantly greater reduction in waist circumference (SMD, 0.35; 95% CI, 0.04−0.66; 9 RCTs; N = 575) but not waist to hip ratio (SMD, 0.32; 95% CI, −0.28 to 0.91; 3 RCTs; N = 263). Heterogeneity was 69%−80%.

3. Metformin was associated with significantly greater reduction in fasting glucose (SMD, 0.65; 95% CI, 0.35−0.95; 17 RCTs; N = 1,281), glycosylated hemoglobin (SMD, 0.38; 95% CI, 0.07−0.69; 4 RCTs; N = 383), fasting insulin (SMD, 0.64; 95% CI, 0.25−1.03; 11 RCTs; N = 787), and insulin resistance (SMD, 0.75; 95% CI, 0.40−1.11; 11 RCTs; N = 680). Heterogeneity was 53%−85%.

4. Metformin was associated with significantly greater reduction in serum total cholesterol (SMD, 0.51; 95% CI, 0.20−0.82; 8 RCTs; N = 628) and triglycerides (SMD, 0.56; 95% CI, 0.13−0.98; 11 RCTs; N = 856) but not LDL cholesterol (SMD, 0.03; 95% CI, −0.35 to 0.41). Metformin significantly increased HDL cholesterol (SMD, 0.45; 95% CI, 0.00−0.90; 7 RCTs; 95% CI, N = 542). Heterogeneity was 72%−89%.

5. Metformin significantly lowered leptin levels but did not impact systolic or diastolic blood pressure.

6. Metformin was significantly associated with diarrhea (NNH, 6) and nausea/vomiting (NNH, 16) but no other adverse event. Discontinuation rates did not differ significantly between metformin and placebo groups.

*Results presented are from the meta-analysis of Zheng et al.*

**Abbreviations:** BMI = body mass index, CI = confidence interval, NNH = number needed to harm, RCT = randomized controlled trial, SMD = standardized mean difference.

**Table 3. Metformin for Antipsychotic-Related Metabolic Adverse Effects in Schizophrenia**

| 1. Metformin was associated with less weight gain or greater weight loss than placebo (SMD, 0.61; 95% CI, 0.44−0.77; 19 RCTs; N = 1,277). Metformin was correspondingly associated with a significantly greater reduction in BMI (SMD, 0.69). Heterogeneity was 51%−73%. |
| 2. Metformin was associated with significantly greater reduction in waist circumference (SMD, 0.35; 95% CI, 0.04−0.66; 9 RCTs; N = 575) but not waist to hip ratio (SMD, 0.32; 95% CI, −0.28 to 0.91; 3 RCTs; N = 263). Heterogeneity was 69%−80%. |
| 3. Metformin was associated with significantly greater reduction in fasting glucose (SMD, 0.65; 95% CI, 0.35−0.95; 17 RCTs; N = 1,281), glycosylated hemoglobin (SMD, 0.38; 95% CI, 0.07−0.69; 4 RCTs; N = 383), fasting insulin (SMD, 0.64; 95% CI, 0.25−1.03; 11 RCTs; N = 787), and insulin resistance (SMD, 0.75; 95% CI, 0.40−1.11; 11 RCTs; N = 680). Heterogeneity was 53%−85%. |
| 4. Metformin was associated with significantly greater reduction in serum total cholesterol (SMD, 0.51; 95% CI, 0.20−0.82; 8 RCTs; N = 628) and triglycerides (SMD, 0.56; 95% CI, 0.13−0.98; 11 RCTs; N = 856) but not LDL cholesterol (SMD, 0.03; 95% CI, −0.35 to 0.41). Metformin significantly increased HDL cholesterol (SMD, 0.45; 95% CI, 0.00−0.90; 7 RCTs; 95% CI, N = 542). Heterogeneity was 72%−89%. |
| 5. Metformin significantly lowered leptin levels but did not impact systolic or diastolic blood pressure. |
| 6. Metformin was significantly associated with diarrhea (NNH, 6) and nausea/vomiting (NNH, 16) but no other adverse event. Discontinuation rates did not differ significantly between metformin and placebo groups. |

Metformin for Clozapine-Associated Obesity

In a very recent systematic review and meta-analysis, Siskind et al. examined the benefits of metformin specifically for clozapine-associated obesity. They identified 8 placebo-controlled RCTs (3 from Chinese databases) with a pooled sample of 478 patients. These studies were 12–26 weeks in duration. Most studies dosed metformin at 1,000−1,500 mg/d. Important findings from the study are presented in Table 4. In summary, relative to placebo, metformin was associated with greater weight loss, reduction in BMI, and reduction in waist circumference; greater reduction in fasting glucose, triglycerides, and LDL cholesterol level; and greater reduction in fasting insulin and insulin resistance. However, metformin was not associated with an advantage for HDL cholesterol, systolic blood pressure, and diastolic blood pressure outcomes. Metformin was not associated with an increased risk of treatment dropout.

Most analyses had low heterogeneity. The conclusions remained largely unchanged in various sensitivity analyses, including of higher quality studies and of studies that were >3 months in duration. Publication bias could not be assessed as the number of studies in separate analyses was too small.

**Table 4. Metformin for Clozapine-Associated Obesity**

| 1. Metformin was associated with more weight loss (MD, 3.12 kg; 95% CI, 1.37−4.88 kg; 6 RCTs; N = 305) and greater reduction in BMI (MD, 1.18; 95% CI, 0.61−1.76; 6 RCTs; N = 530) than placebo. |
| 2. Metformin was associated with greater reduction in waist circumference than placebo (MD, 1.69 cm; 95% CI, 0.32−3.06 cm; 5 RCTs; N = 303). |
| 3. Metformin was associated with a small but statistically significant reduction in fasting glucose (MD, 0.60 mg/dL; 95% CI, 0.17−1.03 mg/dL; 8 RCTs; N = 478), triglycerides (MD, 0.17 mmol/L; 95% CI, 0.03−0.30 mmol/L; 4 RCTs; N = 282), and LDL cholesterol (MD, 0.10 mmol/L; 95% CI, 0.09−0.30 mmol/L; 3 RCTs; N = 227) as compared with placebo. However, HDL cholesterol outcomes (increase) did not differ significantly between metformin and placebo groups (MD, 0.07 mmol/L; 95% CI, −0.02 to 0.16; 4 RCTs; N = 282). Data for total cholesterol were not presented. |
| 4. Metformin was also associated with a significant reduction in fasting insulin (4 RCTs; N = 266) and insulin resistance (3 RCTs; N = 245) relative to placebo, but not with systolic or diastolic blood pressure changes (3 RCTs; each; N = 145). |
| 5. Dropout did not differ significantly between metformin and placebo groups. |

*Results presented are from the meta-analysis of Siskind et al.*

**Abbreviations:** BMI = body mass index, CI = confidence interval, MD = mean difference, RCT = randomized controlled trial.

**Other Metformin Studies**

Wu et al. described the effect of metformin (1,000 mg/d) on antipsychotic-induced dyslipidemia and other metabolic changes in a pooled analysis of two 24-week, placebo-controlled RCTs; one of these RCTs (n = 39) had previously been published and was part of 2 of the meta-analyses described earlier in this article; the other RCT (n = 162) was unpublished. The RCTs were similar in design. In analyses that controlled for age, sex, duration of illness, patients. Outcomes were also better in short-term relative to intermediate-term trials.
and antipsychotic drug used, metformin was associated with significantly greater benefits (relative to placebo) for weight loss, decrease in BMI, decrease in fasting insulin and insulin resistance, increase in HDL cholesterol, and decrease in total cholesterol, LDL cholesterol, and triglycerides. Fasting glucose was the only metabolic variable that did not differentiate the groups. Whereas some of the benefits appeared by 12 weeks of treatment, others were apparent only at the 24-week treatment endpoint. This suggests that an adequate metformin trial should last for at least 24 weeks.

A Possible Place for Topiramate

Topiramate is emerging as a potential challenger to metformin. In a systematic review and meta-analysis of RCTs of topiramate (100–400 mg/d) augmentation of antipsychotic drugs in schizophrenia spectrum disorders, Correll et al.8 identified 8 trials (pooled N = 439) lasting 8–24 (mean, 13.6) weeks. One study was open-label, and one was a crossover trial. One study included first episode patients, and the rest were conducted in chronically ill patients. Two studies initiated topiramate along with the antipsychotic; in the rest, topiramate was added to a stable dose of ongoing antipsychotic treatment.

Important findings from their meta-analysis are presented in Table 5. In summary, topiramate augmentation was associated with significant benefits with regard to total, positive, negative, and general psychopathology symptoms in schizophrenia. Topiramate was also associated with significant reduction in weight and BMI. Data on other metabolic outcomes were insufficient for meta-analysis. The drug was not associated with an increased risk of study discontinuation.

Heterogeneity was high in most analyses. However, the benefits of topiramate for psychopathology and metabolic outcomes were not mediated or moderated by RCT duration, age, sex, inpatient status, baseline severity of psychopathology, baseline BMI, or dose of topiramate. Importantly, in clozapine-treated patients, topiramate had greater psychopathology benefits but resulted in less weight loss.

Other Possible Pharmacologic Interventions

Nearly 2 dozen pharmacologic interventions have been investigated in the meta-analyses described in this article. There are other possible interventions, as well. For example, melatonin and ramelteon have been found to attenuate some cardiometabolic risk factors in antipsychotic-treated patients with major mental illness.9

In both pediatric10 and adult11 samples, the 677T allele of the methylene tetrahydrofolate reductase gene has been associated with an increased risk of antipsychotic-related metabolic syndrome and of specific elements thereof. This raises the intriguing possibility that the administration of methylfolate supplements may prevent or attenuate the metabolic syndrome in children and adults who receive antipsychotic drugs. The issue merits study because the 677T allele is present in about half of the population.12

There is presently no information about the safety and efficacy of conventional (approved) weight loss treatments in antipsychotic-receiving patients with schizophrenia; these treatments include lorcaserin, liraglutide, the phentermine-topiramate combination, the naltrexone-bupropion combination, and others. However, an important limitation of focusing on weight alone is that there is no evidence that other criteria that define the metabolic syndrome will meaningfully attenuate, as shown with metformin.

Schizophrenia is associated with higher rates of smoking than those observed in the general population, and many studies have examined smoking cessation treatments in schizophrenia; a consideration of this body of research is important but is out of the scope of the present review.

The Many Unknowns

The meta-analyses reviewed in this article provide guidance for pharmacologic interventions (most importantly, metformin) to prevent or treat antipsychotic-related metabolic complications. There are, however, many unknowns. For example, we do not know the best dose of a particular drug and whether there is a dose-dependent effect. We do not know for how long these medications need to be continued. There is no information on the long-term (beyond 6 months) safety and efficacy of these interventions. We do not know whether adding diet and exercise to a pharmacologic strategy would have additive or synergistic benefits, or no additional benefit. We do not know whether specific subgroups of patients benefit less or more; an example is in patients with a genetic mutation for a metabolic syndrome. Given the differences in the vulnerability to and the prevalence of metabolic abnormalities in different ethnic groups, it is important to determine whether the benefits of metformin and other pharmacologic interventions vary with ethnicity. Last, but not least, it is necessary to know whether addressing cardiometabolic risk factors through the use of
metformin makes a difference to hard outcomes such as the incidence of ischemic heart disease events, cerebrovascular disease events, and mortality related thereto; one wonders, though, how such a study would be funded.

Concluding Notes

Patients prescribed antipsychotic medications should be regularly screened for metabolic changes. Among nearly 2 dozen treatments that have been trialed for treating or preventing antipsychotic-related adverse metabolic changes, metformin is the best studied and is associated with the best evidence of short- to intermediate-term efficacy for improving weight, glycemic, and lipid (but not blood pressure) outcomes in patients with schizophrenia. There seems to be a signal for better outcomes with an earlier institution of metformin. Topiramate is emerging as another possible treatment; besides reduced weight, indices of psychopathology may also improve. Finally, in patients who need better antipsychotic control, aripiprazole augmentation is also a possible choice because metabolic outcomes may also be improved;13,14 however, its role as an augmentation agent requires better research.

REFERENCES